Farzad Peiravian

Years Active: 2020-2023
Publications (10 Years): 5

Shahid Beheshti University of Medical Sciences School of Pharmacy

Shahid Beheshti University of Medical Sciences School of Pharmacy (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Shahid Beheshti University of Medical Sciences School of Pharmacy Apr 21 2013

Iran

Assistant Professor :: Pharmacoeconomics and Pharma Management

Education History

Shahid Beheshti University of Medical Sciences School of Pharmacy Sep 23 2008 - Feb 10 2012

Iran

PHD :: Pharmacoeconomics and Pharma Management

Publications

Nazila Yousefi, Alireza Salimi, Ghader Mohammadnezhad, Saeed Taheri, Farzad Peiravian
A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision Medicine. Journal of gastrointestinal cancer (2023)
Nikta Shobeiri, Farzad Peiravian, Nazila Yousefi
How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements? Iranian journal of pharmaceutical research : IJPR 21 (1) (2022)
Azin Kadkhodamanesh, Vida Varahrami, Leila Zarei, Farzad Peiravian, Mohammad Hadidi, Nazila Yousefi
Investigation the determinants of pharmaceutical expenditure share of GDP in Iran and selected OECD countries. Journal of pharmaceutical policy and practice 14 (1) (2021)
Nazila Yousefi, Mahyar Polroudi Moghaddam, Gita Afsharmanesh, Farzad Peiravian
Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment. The International journal of health planning and management 35 (6) (2020)
Behzad Fatemi, Soheila Rezaei, Saeed Taheri, Farzad Peiravian
Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience. Expert review of pharmacoeconomics & outcomes research 21 (4) (2020)

Farzad Peiravian.css-eqlu8i{font-size:small;padding-left:4px;}